Literature DB >> 25385100

Arthritis and benznidazole: more closely related than we thought.

E Aldasoro1, M J Pinazo2, I Oliveira2, J Munoz2, E Posada2, A Requena-Méndez2, N Serret2, J Gascon1.   

Abstract

Chagas disease is a parasitic infection that leads to a significant public health problem in countries where the disease is endemic and where it is nonendemic. Benznidazole is the most commonly used drug for the etiological treatment of Chagas disease. Patients treated with benznidazole suffer frequent adverse drug reactions. Although arthralgia is common, arthritis has been reported as a very rare side effect. The objective of this study was to describe arthritis in a cohort of Trypanosoma cruzi-infected patients treated with benznidazole.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25385100      PMCID: PMC4291430          DOI: 10.1128/AAC.04078-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  Severe invalidating pain syndrome associated with benznidazole therapy for Chagas' disease.

Authors:  Concepción Moll; Pilar Peris; Asunción Moreno; José Muñoz; Nuria Guañabens
Journal:  Clin Rheumatol       Date:  2007-08-17       Impact factor: 2.980

Review 2.  Antibodies against cyclic citrullinated peptides in infectious diseases--a systematic review.

Authors:  Isabella Lima; Mittermayer Santiago
Journal:  Clin Rheumatol       Date:  2010-08-05       Impact factor: 2.980

3.  Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial.

Authors:  Rodolfo Viotti; Carlos Vigliano; Bruno Lococo; Graciela Bertocchi; Marcos Petti; María Gabriela Alvarez; Miriam Postan; Alejandro Armenti
Journal:  Ann Intern Med       Date:  2006-05-16       Impact factor: 25.391

4.  Tolerance of benznidazole in treatment of Chagas' disease in adults.

Authors:  María-Jesús Pinazo; José Muñoz; Elizabeth Posada; Paulo López-Chejade; Montserrat Gállego; Edgar Ayala; Elena del Cacho; Dolors Soy; Joaquim Gascon
Journal:  Antimicrob Agents Chemother       Date:  2010-09-07       Impact factor: 5.191

5.  Long term evaluation of etiological treatment of chagas disease with benznidazole.

Authors:  J Romeu Cancado
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2002 Jan-Feb       Impact factor: 1.846

Review 6.  Drug-induced lupus.

Authors:  Andrea T Borchers; Carl L Keen; M Eric Gershwin
Journal:  Ann N Y Acad Sci       Date:  2007-06       Impact factor: 5.691

Review 7.  Evaluation and treatment of chagas disease in the United States: a systematic review.

Authors:  Caryn Bern; Susan P Montgomery; Barbara L Herwaldt; Anis Rassi; Jose Antonio Marin-Neto; Roberto O Dantas; James H Maguire; Harry Acquatella; Carlos Morillo; Louis V Kirchhoff; Robert H Gilman; Pedro A Reyes; Roberto Salvatella; Anne C Moore
Journal:  JAMA       Date:  2007-11-14       Impact factor: 56.272

Review 8.  Chagas disease in Spain, the United States and other non-endemic countries.

Authors:  Joaquim Gascon; Caryn Bern; María-Jesús Pinazo
Journal:  Acta Trop       Date:  2009-07-29       Impact factor: 3.112

Review 9.  Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities.

Authors:  Rodolfo Viotti; Carlos Vigliano; Bruno Lococo; Maria Gabriela Alvarez; Marcos Petti; Graciela Bertocchi; Alejandro Armenti
Journal:  Expert Rev Anti Infect Ther       Date:  2009-03       Impact factor: 5.091

10.  Towards a paradigm shift in the treatment of chronic Chagas disease.

Authors:  R Viotti; B Alarcón de Noya; T Araujo-Jorge; M J Grijalva; F Guhl; M C López; J M Ramsey; I Ribeiro; A G Schijman; S Sosa-Estani; F Torrico; J Gascon
Journal:  Antimicrob Agents Chemother       Date:  2013-11-18       Impact factor: 5.191

View more
  3 in total

1.  Severe immune thrombocytopaenia in a patient taking benznidazole for chronic Chagas disease.

Authors:  Clara Crespillo-Andújar; María Calbacho Robles; Francesca F Norman; Jose A Pérez-Molina
Journal:  BMJ Case Rep       Date:  2018-03-27

2.  Safety Profile of Benznidazole in the Treatment of Chronic Chagas Disease: Experience of a Referral Centre and Systematic Literature Review with Meta-Analysis.

Authors:  Clara Crespillo-Andújar; Emmanuele Venanzi-Rullo; Rogelio López-Vélez; Begoña Monge-Maillo; Francesca Norman; Ana López-Polín; José A Pérez-Molina
Journal:  Drug Saf       Date:  2018-11       Impact factor: 5.228

3.  Chagas disease and systemic autoimmune diseases among Bolivian patients in Switzerland.

Authors:  Yves Jackson; Drenusha Vieira de Mello Pula; Axel Finckh; Carlo Chizzolini; François Chappuis
Journal:  Mem Inst Oswaldo Cruz       Date:  2018-02-05       Impact factor: 2.743

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.